Publications by authors named "Ann Pope"

Claim this Profile
S
SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.
Rossa Brugha, Amanda Kirkham, Jessica Bate, G A Amos Burke, Ana Hughes, Ann M Pope

J Pediatr· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
Richard T Bryan, Wenyu Liu, Sarah J Pirrie, Rashid Amir, Jean Gallagher, Ann M Pope

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
Richard T Bryan, Wenyu Liu, Sarah J Pirrie, Rashid Amir, Jean Gallagher, Ann M Pope

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.
Hayley Colton, Natalie Barratt, Nigel Temperton, Hailey Hornsby, Adrienn Angyal, Ann Pope

Br J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.
Nicholas James, Sarah Pirrie, Wenyu Liu, James Catto, Kieran Jefferson, Ann Pope

Health Technol Assess· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Eleanor Barnes, Carl S Goodyear, Michelle Willicombe, Charlotte Gaskell, Stefan Siebert, Ann Pope

Nat Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer.
Nicholas D James, Ayesha Ali, Ann Pope, Amisha Desai, Daniel Ford

BJUI Compass· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.
Richard T Bryan, Wenyu Liu, Sarah J Pirrie, Rashid Amir, Jean Gallagher, Ann M Pope

Eur Urol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial.
Harriet P Mintz, Amandeep Dosanjh, Helen M Parsons, Ana Hughes, Alicia Jakeman, Ann M Pope

Pilot Feasibility Stud· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
Wei Shen Tan, Anesh Panchal, Laura Buckley, Adam J Devall, Laurence S Loubière, Ann M Pope

Eur Urol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, Ann Pope, Darren Barton

BJU Int· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Nicholas James, Sarah Pirrie, Ann Pope, Darren Barton, Lazaros Andronis

Health Technol Assess· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
Nicholas D James, Sarah J Pirrie, Ann M Pope, Darren Barton, Lazaros Andronis

JAMA Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis